Nonsteroidal. anti-inflammatory drugs and cancer prevention

Annual Review of Medicine

Volumn 51, Issue , 2000, Pages 511-523

  Baron, John A ^a   Sandler, Robert S ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Adenoma; Aspirin; Colorectal neoplasms; Sulindac

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; SULINDAC;

ADENOMA; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON POLYPOSIS; COLORECTAL CANCER; DRUG MECHANISM; ENZYME INHIBITION; ESOPHAGUS CANCER; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH CANCER;

ADENOMA; ADENOMATOUS POLYPOSIS COLI; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; HUMANS;

EID: 0034009433     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.51.1.511     Document Type: Review

References (69)

1. 1. Kune GA, Kune S, Watson LF. 1988. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 48:4399-404
2. 2. Rosenberg L, Palmer JR, Zauber AG, et al. 1991. A hypothesis: nonsteroidal antiinflammatory drugs reduce the incidence of large-bowel cancer. J. Natl. Cancer Inst. 83:355-58
3. 3. Thun MJ, Namboodiri MM, Calle EE, et al. 1993. Aspirin use and risk of fatal cancer. Cancer Res. 53:1322-27
4. 4. Thun MJ, Namboodiri MM, Heath CW Jr. 1991. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325:1593-96
5. 5. Suh O, Mettlin C, Petrelli NJ. 1993. Aspirin use, cancer, and polyps of the large bowel. Cancer 72:1171-77
6. 6. Muscat JE, Stellman SD, Wynder EL. 1994. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 74:1847-54
7. 7. Giovannucci E, Egan KM, Hunter DJ, et al. 1995. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333:609-14
8. 8. Peleg II, Maibach HT, Brown SH, Wilcox CM. 1994. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch. Intern. Med. 154:394-99
9. 9. Schreinemachers DM, Everson RB. 1994. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138-46
10. 10. International Agency for Research on Cancer, World Health Organization. 1997. Handbooks for Cancer Prevention, Vol 1. Lyon, France: Int. Agency Res. Cancer
11. 11. Paganini-Hill A, Chao A, Ross RK, Henderson BE. 1989. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 299:1247-50
12. 12. Smalley W, Ray WA, Daugherty J, Griffin MR. 1999. Use of nonsteroidal antiinflammatory drugs and incidence of colorectal cancer: a population-based study. Arch. Intern. Med. 159:161-66
13. 13. Greenberg ER, Baron JA, Freeman DH Jr, et al. 1993. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J. Natl. Cancer Inst. 85:912-16
14. 14. Logan R, Little J, Hawtin P, Hardcastle JD. 1993. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in Nottingham faecal occult blood screening programme. BMJ 307:285-89
15. 15. Giovannucci E, Rimm EB, Stampfer MJ, et al. 1994. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 121:241-46
16. 16. Sandler RS, Galanko JC, Murray SC, et al. 1998. Aspirin and nonsteroidal antiinflammatory agents and risk for colorectal adenomas. Gastroenterology 114: 441-47
17. 17. Reeves MJ, Newcomb PA, Trentham-Dietz A, et al. 1996. Nonsteroidal antiinflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol., Biomarkers Prev. 5:955-60
18. 18. Gann PH, Manson JE, Glynn RJ, et al. 1993. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J. Natl. Cancer Inst. 85:1220-24
19. 19. Sturmer T, Glynn RJ, Lee IM, et al. 1998. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann. Intern. Med. 128:713-20
20. 20. Hixson LJ, Earnest DL, Fennerty MB, Sampliner RE. 1993. NSAID effect on sporadic colon polyps. Am. J. Gastroenterol 88:1652-56
21. 21. Matsuhashi N, Nakajima A, Fukushima Y, et al. 1997. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 40:344-49
22. 22. Ladenheim J, Garcia G, Titzer D, et al. 1995. Effect of sulindac on sporadic colonic polyps. Gastroenterology 108: 1083-87
23. 23. DiSario J, Alberts D, Tietze C, et al. 1996. Sulindac induces regression and prevents progression of sporadic colorectal adenomas. Gastroenterology 112: A555 (Abstr.)
24. 24. Kinzler KW, Vogelstein B. 1996. Lessons from hereditary colorectal cancer. Cell 87:159-70
25. 25. Waddell WR, Loughry RW. 1983. Sulindac for polyposis of the colon. J. Surg. Oncol. 24:83-87
26. 26. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. 1989. Sulindac for polyposis of the colon. Am. J. Surg. 157:175-79
27. 27. Labayle D, Fischer D, Vielh P, et al. 1991. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635-39
28. 28. Giardiello FM, Hamilton SR, Krush AJ, et al. 1993. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328:1313-16
29. 29. Lynch HT, Thorson AG, Smyrk T. 1995. Rectal cancer after prolonged sulindac chemoprevention. A case report. Cancer 75:936-38
30. 30. Nugent KP, Farmer KC, Spigelman AD, et al. 1993. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg. 80:1618-19
31. 31. Richard CS, Berk T, Bapat BV, et al. 1997. Sulindac for periampullary polyps in FAP patients. Int. J. Color. Dis. 12:14-18
32. 32. Levy GN. 1997. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J. 11:234-47
33. 33. Lynch NR, Castes M, Astoin M, Salomon JC. 1978. Mechanism of inhibition of tumour growth by aspirin and indomethacin. Br. J. Cancer 38:503-12
34. 34. Trevisani A, Ferretti E, Capuzzo A, Tomasi V. 1980. Elevated levels of prostaglandin E2 in Yoshida hepatoma and the inhibition of tumour growth by nonsteroidal anti-inflammatory drugs. Br. J. Cancer 41:341-47
35. 35. Verma AK, Ashendel CL, Boutwell RK. 1980. Inhibition by prostaglandin synthesis inhibitors of the induction of epidermal ornithine decarboxylase activity, the accumulation of prostaglandins, and tumor promotion caused by 12-O-tetra-decanoylphorbol-13-acetate. Cancer Res. 40:308-15
36. 36. Narisawa T, Satoh M, Sano M, Takahashi T. 1983. Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis 4:1225-27
37. 37. Pollard M, Luckert PH. 1983. Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J. Natl. Cancer Inst. 70:1103-5
38. 38. Reddy BS, Maruyama H, Kelloff G. 1987. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res. 47:5340-46
39. 39. Boolbol SK, Dannenberg AJ, Chadburn A, et al. 1996. Cyclooxygenase-2 over-expression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56:2556-60
40. 40. Chiu CH, McEntee MF, Whelan J. 1997. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res. 57:4267-73
41. 41. Jacoby RF, Marshall DJ, Newton MA, et al. 1996. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal antiinflammatory drug piroxicam. Cancer Res. 56:710-14
42. 42. Garidou A, Tzonou A, Lipworth L, et al. 1996. Life-style factors and medical conditions in relation to esophageal cancer by histologie type in a low-risk population. Int. J. Cancer 68:295-99
43. 43. Funkhouser EM, Sharp GB. 1995. Aspirin and reduced risk of esophageal carcinoma. Cancer 76:1116-19
44. 44. Farrow DC, Vaughan TL, Hansten PD, et al. 1998. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol., Biomarkers Prev. 7:97-102
45. 45. Harris RE, Kasbari S, Farrar WB. 1999. Prospective study of nonsteroidal antiinflammatory drugs and breast cancer. Oncol. Rep. 6:71-73
46. 46. Harris RE, Namboodiri KK, Farrar WB. 1996. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7:203-5
47. 47. Egan KM, Stampfer MJ, Giovannucci E, et al. 1996. Prospective study of regular aspirin use and the risk of breast cancer. J. Natl. Cancer Inst. 88:988-93
48. 48. Thomas DR, Philpott GW, Jaffe BM. 1974. The relationship between concentration of prostaglandin E and rates of cell replication. Exp. Cell Res. 84:40-46
49. 49. de Mello MC, Bayer BM, Beaven MA. 1980. Evidence that prostaglandins do not have a role in the cytostatic action of anti-inflammatory drugs. Biochem. Pharm. 29:311-18
50. 50. Hixson LJ, Alberts DS, Krutzsch M, et al. 1994. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol. Biomarkers Prev. 3:433-38
51. 51. Shiff SJ, Koutsos MI, Qiao L, Rigas B. 1996. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp. Cell Res. 222:179-88
52. 52. Shiff SJ, Rigas B. 1997. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 113:1992-98
53. 53. Viaje A, Slaga TJ, Wigler M, Weinstein IB. 1977. Effects of antiinflammatory agents on mouse skin tumor promotion, epidermal DNA synthesis, phorbol ester-induced cellular proliferation, and production of plasminogen activator. Cancer Res. 37:1530-36
54. 54. Furstenberger G, Marks F. 1978. Indomethacin inhibition of cell proliferation induced by the phorbolester TPA is reversed by prostaglandin E2 in mouse epidermis in vivo. Biochem. Biophys. Res. Commun. 84:1103-11
55. 55. Narisawa T, Takahashi M, Niwa M, et al. 1987. Involvement of prostaglandin E2 in bile acid-caused promotion of colon carcinogenesis and anti-promotion by the cyclooxygenase inhibitor indomethacin. Jpn. J. Cancer Res. 78:791-98
56. 56. Kulkarni N, Zang E, Kelloff G, Reddy BS. 1992. Effect of the chemopreventive agents piroxicam and D,L-alpha-difluoromethylornithine on intermediate biomarkers of colon carcinogenesis. Carcinogenesis 13:995-1000
57. 57. DeRubertis FR, Craven PA, Saito R. 1985. 16,16-Dimethyl prostaglandin E2 suppresses the increases in the proliferative activity of rat colonie epithelium induced by indomethacin and aspirin. Gastroenterology 89:1054-63
58. 58. Spagnesi MT, Tonelli F, Dolara P, et al. 1994. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 106:362-66
59. 59. Pasricha PJ, Bedi A, O'Connor K, et al. 1995. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 109:994-98
60. 60. Earnest D, Hixson L, Fennerty J, et al. 1993. Excellent agreement between 3 methods of measuring rectal epithelial cell proliferation in patients with resected colon cancer but lack of evidence of a suppressive effect by piroxicam treatment. Gastroenterology 104:A396 (Abstr.)
61. 61. Aoki T, Ruffin M, Kraus E, et al. 1996. Epithelial cell proliferation and prostaglandin (PG) release in rectal mucosa of healthy subjects treated with aspirin. Gastroenterology 110:A484 (Abstr.)
62. 62. Watson A. 1997. Sulidac sulfide induces apoptosis in the small intestine by inhibition of COX-1 but not COX-2. Gastroenterology 112:A678
63. 63. Taketo MM. 1998. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J. Natl. Cancer Inst. 90:1609-20
64. 64. Samaha HS, Kelloff GJ, Steele V, et al. 1997. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res. 57:1301-5
65. 65. Lupulescu A. 1996. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot. Essent. Fatty Acids 54:83-94
66. 66. Plescia OJ, Smith AH, Grinwich K. 1975. Subversion of immune system by tumor cells and role of prostaglandins. Proc. Natl. Acad. Sci. USA 72:1848-51
67. 67. Skinner SA, Penney AG, O'Brien PE. 1991. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch. Surg. 126:1094-96
68. 68. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. 1998. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. USA 95:681-86
69. 69. Piazza GA, Rahm AL, Krutzsch M, et al. 1995. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55: 3110-16